Lexeo Therapeutics (LXEO) Stock Forecast: StockMap's 2-Week Call
LXEO stock forecast: StockMap's model leans Underperform on Lexeo Therapeutics for the two weeks after the Nov 19 close, toward LXEO trailing the growth index. It is a lean inside the no-call band, not a call, and not a price target. Right in 5 of 6 two-week windows on LXEO since Aug 21; by chance, a call on the same dates was right 59% of the time.
Lexeo Therapeutics last closed at $2.95, +0.00% on the session.
Against the IVW growth benchmark the position is +2.33% over the forecast window.
Lexeo Therapeutics' market cap is $244.23M as of November 19, 2026.
Leans down ↘: a small lean, not a call · the next 2 weeks, vs S&P 500 growth. The lean on a scale from −100 to +100 is -45 (too close to call).
Where LXEO sits: sized by market cap, coloured by the day's move.
The read is built from 15 underlying insights — 4 bullish and 11 bearish.
Agreement across those insights is 73%.
47 daily calls for LXEO so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.
On the fundamentals StockMap ranks Lexeo Therapeutics in the 19th percentile on return on equity, where 100 is best.
Lexeo Therapeutics is classified under Health Care / Biotechnology.
StockMap tracks Lexeo Therapeutics as the 223rd largest of the 394 companies it covers in the Biotechnology industry, part of the Health Care sector.
Across that group the current two-week reads are 200 Moderate Underperform, 134 Neutral, 43 Strong Underperform and 17 Moderate Outperform.
On that composite Lexeo Therapeutics ranks 333rd of 394 in the group, against a group median of -0.27.